From: Antipsychotic polypharmacy in a regional health service: a population-based study
Monotherapy (N = 47,386) | Combination with one oral antipsychotics (N = 5,692) | Combination with ≥2 antipsychotics(N = 4,163) | ||
---|---|---|---|---|
FGA | SGA | |||
Risperidone LAI | 654 (1.4%) | 95 (1.6%) | 445 (7.8%) | 948 (22.7%) |
Fluphenazine | 212 (0.4%) | 49 (0.8%) | 74 (1.3%) | 405 (9.7%) |
Zuclopenthixol LAI | 202 (0.4%) | 46 (0.8%) | 178 (3.1%) | 424 (10.1%) |
Pipothiazine | 70 (0.1%) | 27 (0.4%) | 49 (0.8%) | 111 (2.6%) |
TOTAL LAI | 1,138 (2.4%) | 217 (3.8%) | 746 (13.1%) | 1,699 (40.8%) |